169 related articles for article (PubMed ID: 1706136)
1. [Evaluation of anti-androgen therapy for benign prostatic hypertrophy by using transrectal prostatic ultrasonography].
Kazama T; Mizuno I; Takamine T; Umeda K; Terada T; Ishikawa S; Fuse H; Katayama T
Hinyokika Kiyo; 1990 Dec; 36(12):1423-7. PubMed ID: 1706136
[TBL] [Abstract][Full Text] [Related]
2. [Clinical results and problems of anti-androgen therapy of benign prostatic hypertrophy].
Umeda K
Hinyokika Kiyo; 1991 Nov; 37(11):1429-33. PubMed ID: 1722628
[TBL] [Abstract][Full Text] [Related]
3. [Clinical studies on morphological changes in the prostate in patients with benign prostatic hypertrophy after antiandrogen therapy--by means of transrectal ultrasonotomography].
Suzuki K; Ichinose Y; Hashimoto K; Matsumoto K; Suzuki T; Imai K; Yamanaka H
Hinyokika Kiyo; 1990 May; 36(5):557-60. PubMed ID: 1698012
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of the long-term effect of anti-androgen therapy by sonometrics in patients with benign prostatic hypertrophy].
Kimura A; Higuchi T
Nihon Hinyokika Gakkai Zasshi; 1988 Oct; 79(10):1697-702. PubMed ID: 2471862
[No Abstract] [Full Text] [Related]
5. [Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism].
Iguchi H; Ikeuchi T; Kai Y; Yoshida H
Hinyokika Kiyo; 1994 Mar; 40(3):215-9. PubMed ID: 7513937
[TBL] [Abstract][Full Text] [Related]
6. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H
J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
[TBL] [Abstract][Full Text] [Related]
7. Regression of prostatic hypertrophy by osaterone acetate in dogs.
Tsutsu T; Hori T; Shimizu M; Orima H; Kawakami E; Fukuda S
J Vet Med Sci; 2000 Oct; 62(10):1115-9. PubMed ID: 11073087
[TBL] [Abstract][Full Text] [Related]
8. [Clinical effects of chlormadinone acetate (Prostal) on patients with prostatic hypertrophy--with reference to estimation of size and weight of prostate by means of transrectal ultrasonotomography].
Yoshida H; Haraguchi C; Ogawa Y; Kawai N; Ohyama M; Higaki Y; Saitoh T; Imamura K
Hinyokika Kiyo; 1983 Nov; 29(11):1419-26. PubMed ID: 6203377
[TBL] [Abstract][Full Text] [Related]
9. [Antiandrogen therapy of benign prostatic hypertrophy: clinical effects of allylestrenol evaluated by transrectal ultrasonographic measurement].
Tsuji Y; Ariyoshi A; Nakamura H; Michinaga S; Tomita Y; Ohmori A; Tahara H; Yamashita Y; Fujisawa Y; Kajiwara I
Hinyokika Kiyo; 1992 Aug; 38(8):961-6. PubMed ID: 1384295
[TBL] [Abstract][Full Text] [Related]
10. Chlormadinone acetate pellet implantation plus short-term oral administration in dogs with benign prostatic hypertrophy.
Kawakami E; Shimizu M; Orima H; Fujita M; Hori T; Tsutsui T
Int J Androl; 1998 Apr; 21(2):67-73. PubMed ID: 9675615
[TBL] [Abstract][Full Text] [Related]
11. [Studies of mechanisms of the action of androgens on prostate. 3. Anti-androgenic effect of gestagenic compounds and treatment of benign prostatic hypertrophy with chlormadinone acetate].
Shida K; Shimazaki J; Urano E; Kurihara H; Takahashi H
Nihon Hinyokika Gakkai Zasshi; 1972 Feb; 63(2):109-28. PubMed ID: 4113183
[No Abstract] [Full Text] [Related]
12. Effects of a new steroidal antiandrogen, TZP-4238 (17 alpha-acetoxy-6-chloro-2-oxa-4, 6-pregnadiene-3, 20-dione), on spontaneously developed canine benign prostatic hyperplasia.
Takezawa Y; Ito K; Suzuki K; Fukabori Y; Yamanaka H; Honma S; Mieda M; Hamataki N; Kushitani M
Prostate; 1995 Dec; 27(6):321-8. PubMed ID: 7501544
[TBL] [Abstract][Full Text] [Related]
13. Short-term oral treatment of canine benign prostatic hypertrophy with chlormadinone acetate.
Orima H; Shimizu M; Tsutsui T; Kawakami E; Ogasa A
J Vet Med Sci; 1995 Feb; 57(1):139-41. PubMed ID: 7538794
[TBL] [Abstract][Full Text] [Related]
14. [Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results].
Kanimoto Y; Okada K
Hinyokika Kiyo; 1991 Nov; 37(11):1423-8. PubMed ID: 1722627
[TBL] [Abstract][Full Text] [Related]
15. Relationship between prostatic atrophy and apoptosis in the canine spontaneous benign prostatic hyperplasia (BPH) following chlormadinone acetate (CMA).
Murakoshi M; Ikeda R; Fukui N; Nakayama T
Tokai J Exp Clin Med; 2001 Jul; 26(2):71-5. PubMed ID: 11806444
[TBL] [Abstract][Full Text] [Related]
16. Effects of oral administration of chlormadinone acetate on canine prostatic hypertrophy.
Kawakami E; Tsutsui T; Shimizu M; Orima H; Makanae Y; Yajima K; Ogasa A
J Vet Med Sci; 1993 Aug; 55(4):631-5. PubMed ID: 7691191
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of TZP-4238 on patients with benign prostatic hypertrophy--with special reference to urodynamics].
Park YC; Akiyama T; Kurita T; Kaneko S; Mizunaga M; Yachiku S
Hinyokika Kiyo; 1994 Aug; 40(8):761-9. PubMed ID: 7524292
[TBL] [Abstract][Full Text] [Related]
18. [Three-dimensional display of the prostate based on transrectal ultrasonogram].
Kimura A; Aso Y
Nihon Hinyokika Gakkai Zasshi; 1992 Sep; 83(9):1490-8. PubMed ID: 1279262
[TBL] [Abstract][Full Text] [Related]
19. Antiandrogenic treatment of benign prostatic hyperplasia: a placebo controlled trial.
Ostri P; Swartz R; Meyhoff HH; Petersen JH; Lindgård G; Frimodt-Møller C; Andersson T; Nielsen MS
Urol Res; 1989; 17(1):29-33. PubMed ID: 2466359
[TBL] [Abstract][Full Text] [Related]
20. Effect of osaterone acetate administration on prostatic regression rate, peripheral blood hormone levels and semen quality in dogs with benign prostatic hypertrophy.
Tsutsui T; Hori T; Shimizu M; Tatsuzawa C; Kawakami E
J Vet Med Sci; 2001 Apr; 63(4):453-6. PubMed ID: 11346183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
